Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, Marco Iudicello, Cinzia Cordioli, Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, Luigi Lavorgna, Giorgia Teresa Maniscalco, Erica Curti, Lorena Lorefice, Eleonora Cocco, Viviana Nociti, Massimiliano Mirabella, Damiano Baroncini, Giorgia Mataluni, Doriana Landi, Martina Petruzzo, Roberta LanzilloIlaria Gandoglia, Alice Laroni, Rita Frangiamore, Arianna Sartori, Paola Cavalla, Gianfranco Costantini, Maria Pia Sormani, Ruggero Capra

Research output: Contribution to journalArticle

Abstract

Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14 Italian centers), retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Patients were grouped in 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Three hundred and sixty patients were enrolled. Median dose interval (MDI) following 24th infusion was 4.7 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Two hundred and sixteen patients were in the SID group (MDI = 4.3 weeks) and 144 in the EID group (MDI 6.2 weeks). Annualized relapse rate was 0.060 (95% CI = 0.033–0.087) in the SID group and 0.039 (95% CI = 0.017–0.063) in the EID group. The non-inferiority of EID versus SID was satisfied. In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID setting. This observation confirms previous results and together with the emerging evidence of a reduced risk of PML associated to an EID, supports the need of a randomized study to assess the need to change the standard of the natalizumab dosing schedule.

Original languageEnglish
JournalNeurotherapeutics
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Progressive Multifocal Leukoencephalopathy
Natalizumab
Appointments and Schedules
Cohort Studies
Retrospective Studies
Recurrence

Keywords

  • efficacy
  • extended dose
  • Multiple sclerosis
  • natalizumab
  • progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Clerico, M., De Mercanti, S. F., Signori, A., Iudicello, M., Cordioli, C., Signoriello, E., ... Capra, R. (Accepted/In press). Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? Neurotherapeutics. https://doi.org/10.1007/s13311-019-00776-7

Extending the Interval of Natalizumab Dosing : Is Efficacy Preserved? / Clerico, Marinella; De Mercanti, Stefania Federica; Signori, Alessio; Iudicello, Marco; Cordioli, Cinzia; Signoriello, Elisabetta; Lus, Giacomo; Bonavita, Simona; Lavorgna, Luigi; Maniscalco, Giorgia Teresa; Curti, Erica; Lorefice, Lorena; Cocco, Eleonora; Nociti, Viviana; Mirabella, Massimiliano; Baroncini, Damiano; Mataluni, Giorgia; Landi, Doriana; Petruzzo, Martina; Lanzillo, Roberta; Gandoglia, Ilaria; Laroni, Alice; Frangiamore, Rita; Sartori, Arianna; Cavalla, Paola; Costantini, Gianfranco; Sormani, Maria Pia; Capra, Ruggero.

In: Neurotherapeutics, 01.01.2019.

Research output: Contribution to journalArticle

Clerico, M, De Mercanti, SF, Signori, A, Iudicello, M, Cordioli, C, Signoriello, E, Lus, G, Bonavita, S, Lavorgna, L, Maniscalco, GT, Curti, E, Lorefice, L, Cocco, E, Nociti, V, Mirabella, M, Baroncini, D, Mataluni, G, Landi, D, Petruzzo, M, Lanzillo, R, Gandoglia, I, Laroni, A, Frangiamore, R, Sartori, A, Cavalla, P, Costantini, G, Sormani, MP & Capra, R 2019, 'Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?', Neurotherapeutics. https://doi.org/10.1007/s13311-019-00776-7
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E et al. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? Neurotherapeutics. 2019 Jan 1. https://doi.org/10.1007/s13311-019-00776-7
Clerico, Marinella ; De Mercanti, Stefania Federica ; Signori, Alessio ; Iudicello, Marco ; Cordioli, Cinzia ; Signoriello, Elisabetta ; Lus, Giacomo ; Bonavita, Simona ; Lavorgna, Luigi ; Maniscalco, Giorgia Teresa ; Curti, Erica ; Lorefice, Lorena ; Cocco, Eleonora ; Nociti, Viviana ; Mirabella, Massimiliano ; Baroncini, Damiano ; Mataluni, Giorgia ; Landi, Doriana ; Petruzzo, Martina ; Lanzillo, Roberta ; Gandoglia, Ilaria ; Laroni, Alice ; Frangiamore, Rita ; Sartori, Arianna ; Cavalla, Paola ; Costantini, Gianfranco ; Sormani, Maria Pia ; Capra, Ruggero. / Extending the Interval of Natalizumab Dosing : Is Efficacy Preserved?. In: Neurotherapeutics. 2019.
@article{20900efed48d4a25887e3f6b3f564b08,
title = "Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?",
abstract = "Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14 Italian centers), retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Patients were grouped in 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Three hundred and sixty patients were enrolled. Median dose interval (MDI) following 24th infusion was 4.7 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Two hundred and sixteen patients were in the SID group (MDI = 4.3 weeks) and 144 in the EID group (MDI 6.2 weeks). Annualized relapse rate was 0.060 (95{\%} CI = 0.033–0.087) in the SID group and 0.039 (95{\%} CI = 0.017–0.063) in the EID group. The non-inferiority of EID versus SID was satisfied. In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID setting. This observation confirms previous results and together with the emerging evidence of a reduced risk of PML associated to an EID, supports the need of a randomized study to assess the need to change the standard of the natalizumab dosing schedule.",
keywords = "efficacy, extended dose, Multiple sclerosis, natalizumab, progressive multifocal leukoencephalopathy",
author = "Marinella Clerico and {De Mercanti}, {Stefania Federica} and Alessio Signori and Marco Iudicello and Cinzia Cordioli and Elisabetta Signoriello and Giacomo Lus and Simona Bonavita and Luigi Lavorgna and Maniscalco, {Giorgia Teresa} and Erica Curti and Lorena Lorefice and Eleonora Cocco and Viviana Nociti and Massimiliano Mirabella and Damiano Baroncini and Giorgia Mataluni and Doriana Landi and Martina Petruzzo and Roberta Lanzillo and Ilaria Gandoglia and Alice Laroni and Rita Frangiamore and Arianna Sartori and Paola Cavalla and Gianfranco Costantini and Sormani, {Maria Pia} and Ruggero Capra",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s13311-019-00776-7",
language = "English",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",

}

TY - JOUR

T1 - Extending the Interval of Natalizumab Dosing

T2 - Is Efficacy Preserved?

AU - Clerico, Marinella

AU - De Mercanti, Stefania Federica

AU - Signori, Alessio

AU - Iudicello, Marco

AU - Cordioli, Cinzia

AU - Signoriello, Elisabetta

AU - Lus, Giacomo

AU - Bonavita, Simona

AU - Lavorgna, Luigi

AU - Maniscalco, Giorgia Teresa

AU - Curti, Erica

AU - Lorefice, Lorena

AU - Cocco, Eleonora

AU - Nociti, Viviana

AU - Mirabella, Massimiliano

AU - Baroncini, Damiano

AU - Mataluni, Giorgia

AU - Landi, Doriana

AU - Petruzzo, Martina

AU - Lanzillo, Roberta

AU - Gandoglia, Ilaria

AU - Laroni, Alice

AU - Frangiamore, Rita

AU - Sartori, Arianna

AU - Cavalla, Paola

AU - Costantini, Gianfranco

AU - Sormani, Maria Pia

AU - Capra, Ruggero

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14 Italian centers), retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Patients were grouped in 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Three hundred and sixty patients were enrolled. Median dose interval (MDI) following 24th infusion was 4.7 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Two hundred and sixteen patients were in the SID group (MDI = 4.3 weeks) and 144 in the EID group (MDI 6.2 weeks). Annualized relapse rate was 0.060 (95% CI = 0.033–0.087) in the SID group and 0.039 (95% CI = 0.017–0.063) in the EID group. The non-inferiority of EID versus SID was satisfied. In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID setting. This observation confirms previous results and together with the emerging evidence of a reduced risk of PML associated to an EID, supports the need of a randomized study to assess the need to change the standard of the natalizumab dosing schedule.

AB - Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab. It is an observational, multicenter (14 Italian centers), retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Patients were grouped in 2 categories according to the mean number of weeks between doses: < 5 weeks, SID; ≥ 5 weeks, EID. Three hundred and sixty patients were enrolled. Median dose interval (MDI) following 24th infusion was 4.7 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Two hundred and sixteen patients were in the SID group (MDI = 4.3 weeks) and 144 in the EID group (MDI 6.2 weeks). Annualized relapse rate was 0.060 (95% CI = 0.033–0.087) in the SID group and 0.039 (95% CI = 0.017–0.063) in the EID group. The non-inferiority of EID versus SID was satisfied. In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID setting. This observation confirms previous results and together with the emerging evidence of a reduced risk of PML associated to an EID, supports the need of a randomized study to assess the need to change the standard of the natalizumab dosing schedule.

KW - efficacy

KW - extended dose

KW - Multiple sclerosis

KW - natalizumab

KW - progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=85071446493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071446493&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00776-7

DO - 10.1007/s13311-019-00776-7

M3 - Article

AN - SCOPUS:85071446493

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

ER -